Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
1999-06-30
2009-11-17
Liu, Samuel W. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C514S009100, C530S402000, C530S317000, C424S278100
Reissue Patent
active
RE040987
ABSTRACT:
The invention relates to a novel cyclosporin, the pharmaceutical use thereof and a pharmaceutical composition containing it.
REFERENCES:
patent: 4108985 (1978-08-01), Ruegger et al.
patent: 4210581 (1980-07-01), Ruegger et al.
patent: 4220641 (1980-09-01), Traber et al.
patent: 4288431 (1981-09-01), Traber et al.
patent: 4396542 (1983-08-01), Wenger
patent: 4441644 (1984-04-01), Farian
patent: 4554351 (1985-11-01), Wenger
patent: 4814323 (1989-03-01), Andrieu et al.
patent: 5525590 (1996-06-01), Bollinger et al.
patent: 5639724 (1997-06-01), Cavanak
patent: 5767069 (1998-06-01), Ko et al.
patent: 5948884 (1999-09-01), Lüchinger
patent: 5981479 (1999-11-01), Ko et al.
patent: 6255100 (2001-07-01), Ko et al.
patent: 6444643 (2002-09-01), Steiner et al.
patent: 6927208 (2005-08-01), Wenger et al.
patent: 7439277 (2008-10-01), Scalfaro et al.
patent: 0 056 782 (1984-01-01), None
patent: 0 034 567 (1984-07-01), None
patent: 0 484 281 (1992-05-01), None
patent: 0484281 (1992-06-01), None
patent: 0 194 972 (1992-07-01), None
patent: 2 222 770 (1990-03-01), None
patent: WO 86/02080 (1986-04-01), None
patent: WO 97/04005 (1997-02-01), None
patent: WO 97/18828 (1997-05-01), None
patent: WO 97 04005 (1997-06-01), None
patent: WO 98/028328 (1998-07-01), None
patent: WO 98/028329 (1998-07-01), None
patent: WO 98/028330 (1998-07-01), None
patent: WO 00/01715 (2000-01-01), None
patent: WO 2005/021028 (2005-03-01), None
Balogh-nair, V., et al., “Synthesis activity and toxicity of novel macrocyclic ligands against HIV-1 in Jurkat CEM-SS cell lines,” Cellular and Molecular Biology, 1995, pp. S9-S14, vol. 41 (Suppl. 1).
Bartz, S. R., et al., Inhibitition of human immunodeficiency virus replication by nonimmunosuppressinve analogs of cyclosporin A,Proc. Natl. Acad. Sci. USA, vol. 92, pp. 5381-5385, Jun. 1995.
Baumann, G., et al., “Molecular Mechanisms of Immunosuppression,” Journal of Autoimmunity, (1992) 5 (Supplement A), pp. 67-72.
Baumann, G., et al., “Cyclosporine and its Analogue SDZ IMM 125 Mediate Very Similar Effects on T-Cell Activation—A Comparative Analysis In Vitro,” Transplantation Proceedings, Aug. 1992, pp. 43-48, vol. 24, No. 4, Suppl. 2.
Billich, A., et al., “Mode of Action of SDZ NIM 811, a Nonimmunosuppressive Cyclosporin A Analog with Activity against Human Immunodeficiency Virus (HIV) Type 1: Interference with HIV Protein-Cyclophilin A Interactions,” Journal of Virology, Apr. 1995, pp. 2451-2461, vol. 69, No. 4.
Borel, J. F., et al., “Immunopharmacological Properties of Cyclosporine (Sandimmune®) and (Val2)—Dihydrocyclosporine and Their Prospect in Chronic Inflammation,” advances in Inflammation Research, 1986, pp. 277-291, vol. 11.
Borel, J. F., et al., “The Cyclosporins,” Transplantation Proceedings, Feb. 1989, pp. 810-815, vol. 21, No. 1.
Borel, J. F., et al., “In Vivo Pharmacological Effects of Ciclosporin and Some Analogues,” Advances in Pharmacology, 1996, pp. 115-246, vol. 35.
Cebrat, M., et al., “Immunosuppressive Activity of Hymenistatin I,” Peptides, 1996, pp. 191-196, vol. 17, No. 2.
Dorfman, T., et al., “Active-Site Residues of Cyclophillin A Are Crucial for Its Incorporation into Human Immunodeficiency Virus Type 1 Virions,” Journal of Virology, Sep. 1997, pp. 7110-7113, vol. 71, No. 9.
Fesik, S. W. et al., “NMR Studies of (U-13C)Cyclosporin A Bound to Cyclophillin: Bound Conformation and Portions of Cyclosporin Involved in Binding,” Biochemistry, 1991, pp. 6574-6583, vol. 30, No. 26.
Fliri, H. G., et al., “Cyclosporine: Synthetic Studies. Structure-Activity Relationships, Biosysthesis and Mode of Action,” Biochemistry of Peptide Antibiotics, Walter de Gruyter: New York, 1990, pp. 245-287, Chapter 10.
Fliri, H., et al., “Cyclosporins: Structure-Activity Relationships,” Anals of the New York Academy of Sciences, Nov. 30, 1993, pp. 47-53, vol. 696.
Franke, E.K., et al., “Specific Incorporation of cyclophillin A into HIV-1 virions,” Nature, Nov. 24, 1994, pp. 359-362, vol. 372.
Franke, E. K., et al., “Cyclophillin Binding to the Human Immunodeficiency Virus Type 1 Gag Polyprotein is Mimicked by an Anti-Cyclosporine Antibody,” Journal of Virology, Sep. 1995, pp. 5821-5823, vol. 69, No. 9.
Franke, E. K, et al., “Inhibition of HIV-1 Replication by Cyclosporin A or Related Compound Correlates with the Ability to Disrupt the Gag-Cyclophillin A Interaction,” Virology, 1996, pp. 279-282, vol. 222, Article No. 0421.
Hansson, M. J., et al., “The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain-Derived Mitochondria,” Journal of Bioenergetics and Biomembranes, Aug. 2004, pp. 407-413, vol. 36, No. 4.
Heguy, A., “Inhibition of the HIV REV Transactivator: A New Target for Therapeutic Intervention,” Frontiers in Bioscience, Jun. 1, 1997, pp. 283-297, vol. 2.
Holmes, K. K., et al., “Report of the NIH Aids Research Program Evaluation Natural History, Epidemiology, and Prevention Research Area Review Panel Findings and Recommendations of the Office of AIDS Research Advisory Council,” Jun. 7, 1996, pp. 1-40.
Hubler, F., et al., “Synthetic routes to NetXaa4-cyclosporin A derivates as potential anti-HIV 1 drugs,” Institute of Organic Chemistry, University of Lausanne, Tetrahedron Letters, 2000, pp. 7193-7196, vol. 41.
Inoue, K., et al., “Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C controlled trial,” Journal of Gastroenterology, 2003; pp. 567-572, vol. 38.
Inque, K., et al., “Interferon Combined With Cyclosporine Treatment as an Effective Countemeasure Against Hepatitis C Virus Recurrence in Liver Transplant Patients With End-Stage Hepatitis C Virus Related Disease,” Transplantation Proceedings, 2005, pp. 1233-1234, vol. 37.
Ko, S. Y., et al., “Solid-Phase Total Synthesis of Cyclosporine Analogues,” Helvetica Chimica Acta-1997, pp. 695-705, vol. 80.
Kobel, H., et al., “Directed Biosynthesis of Cyclosporins,” European Journal of Applied Microbiology and Biotechnology, 1982, pp. 237-240, vol. 14.
Levine, A., et al., “Report of the NIH AIDS Research Program Evaluation Working Group of the Office of Aids Research Advisory Council,” pp. 1-57, Mar. 13, 1996-Final.
Meo, T., “The MLR Test in the Mouse,” Immunological Methods, 1979, pp. 227-239.
Mlynar, E., et al., “The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficency virus type 1-infected primary and growth-arrested T-cells,” Journal of General Virology, 1997, pp. 825-835, vol. 78.
Nakagawa, M., et al., “Specific inhibition of hepatitis C virus replication by cyclosporin A,” Biochemical and Biophysical Research Communications, 2004, pp. 42-47, vol. 313.
Nicolli, A., et al., “Interactions of Cyclophillin with the Mitochondrial Inner Membrane and Regulation of the Premeability Transition Pore, a Cyclosporin A-sensitive Channel,” The Journal of Biological Chemistry, Jan. 26, 1996, pp. 2185-2192, vol. 271, No. 4.
O'Keefe, S. J., et al., “FK-506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin,” Nature, Jun. 25, 1992, pp. 692-694, vol. 357.
Papageorgiou, C., et al., “Calcineurin Has A Very Tight-Binding Pocket For The Side Chain of Residue 4 Of Cyclosporin,” Bioorganic & Medicinal Chemistry Letters, 1994, pp. 267-272, vol. 4, No. 2.
Papageorgiou, C., et al., “Improved Binding Affinity for Cyclophilin A by a Cyclosporin Derivitative Singly Modified at Its Effector Domain,” J. Med. Chem. 1994, pp. 3674-3676, vol. 37.
Papageorgiou, C. et al. , “Anti-HIV-1 Activity of a Hydrophilic Cyclosporin Derivative with Improved Binding Affinity To Cyclophill
Mutter Manfred
Rückle Thomas
Wenger Roland M.
Debiopharm S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Liu Samuel W.
LandOfFree
Cyclosporin with improved activity profile does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclosporin with improved activity profile, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclosporin with improved activity profile will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072397